Wegovy Starting Doses Restrictions Will Continue Through The Year
Executive Summary
Supply of the obesity drug has outpaced demand in the US, and Novo Nordisk said that will persist throughout 2023.
You may also be interested in...
Amgen’s Plan To Go Big In Obesity
Competing in the obesity market will require significant investment, which Amgen is preparing for, CEO Robert Bradway told investors during the Morgan Stanley Healthcare conference.
Novo Nordisk STEPs Into Heart Failure
The company’s metabolic juggernaut looks like a winner in obesity plus HFpEF, but making comparisons with approved products is tricky – and meeting demand is trickier still.
Obesity Drug Coverage In Employer-Sponsored Plans On Slow Build Trajectory, Survey Finds
Large employer plan sponsors split on whether to cover GLP-1 drugs for weight loss, according to a recent survey.